Australia's healthcare sector covers plasma therapies, medical imaging software and radiopharmaceuticals. CSL (ASX:CSL), Pro Medicus (ASX:PME) and Telix Pharmaceuticals (ASX:TLX) reported important 2026 developments across earnings, contracts, regulatory approvals and commercial expansion. Their Business models differ considerably, making operating execution, product Demand and development milestones important measures through FY27.

CSL is working through a business reset following significant FY26 Impairment and restructuring charges. Pro Medicus continues to expand its Visage imaging platform through long-term customer contracts, while Telix is building its commercial radiopharmaceutical portfolio and progressing additional diagnostic and therapeutic programs.

CSL

CSL reported FY26 total Revenue of approximately USD 15.8 billion. The company recorded a statutory net loss after tax of USD 2.58 billion, primarily reflecting approximately USD 7.1 billion of pre-tax impairment charges and restructuring costs.

Underlying performance was materially different from the statutory result. Underlying NPATA reached approximately USD 3.10 billion, while underlying net profit after tax was USD 2.84 billion.

The company also incurred approximately USD 799 million in pre-tax restructuring expenses during FY26.

For FY27, CSL expects revenue to remain broadly in line with FY26 on a constant-currency basis. Underlying net profit after tax is expected to increase by approximately 5%.

Pro Medicus

Pro Medicus reported FY26 revenue of approximately AUD 261.7 million, representing growth of 22.9%. Underlying net profit after tax reached AUD 144.7 million.

Underlying EBIT was approximately AUD 196.1 million, representing an EBIT Margin of 74.9%.

The company ended FY26 debt-free with cash and financial Assets of approximately AUD 252.3 million.

Contract activity continued during the year. Pro Medicus signed 10 new agreements carrying a minimum contract value of approximately AUD 407 million and completed six renewals valued at approximately AUD 141 million.

Telix Pharmaceuticals

Telix reported total revenue of approximately USD 477 million for the six months ended 30 June 2026. Revenue from its Precision Medicine imaging portfolio increased during the period.

Adjusted EBITDA reached approximately USD 52 million, while net profit after tax was USD 38 million. Operating Cash Flow was positive at approximately USD 23 million.

The company held cash of around USD 252 million at the end of June 2026 and reported a group gross margin of 55%.

Telix has guided to FY26 base-business revenue of approximately USD 950 million to USD 970 million, with an additional approximately USD 40 million associated with its Regeneron partnership. This would take expected full-year revenue above USD 1 billion.

A significant regulatory development occurred in September 2026 when the US Food and Drug Administration approved Pixclara for PET imaging to assist in differentiating recurrent or progressive glioma from treatment-related change.

Healthcare Sector Outlook

The three businesses operate in different parts of healthcare and therefore face different operating drivers.

CSL's performance depends on plasma collection economics, product demand, Manufacturing efficiency and delivery of restructuring measures.

Pro Medicus operates a software-based model where customer contracts, implementation timelines and transaction volumes influence revenue growth. Expansion within large hospital systems and adjacent medical-imaging applications remains central to its development.

Telix combines commercial diagnostic products with an expanding development pipeline. Revenue growth therefore depends on both existing product sales and successful regulatory and commercial progression of newer products.

Regulatory policy is particularly important for healthcare businesses selling into the United States. Changes in approvals, reimbursement arrangements or healthcare spending can influence commercial outcomes.

Key Risks

CSL faces execution risk as it works through restructuring and portfolio changes following the FY26 impairment charges. Slower-than-expected operational improvement could affect progress against FY27 Earnings expectations.

Pro Medicus depends on continued contract wins and successful implementation across large healthcare customers. Delays in deployment or weaker customer demand could moderate revenue growth.

Telix remains exposed to regulatory and development risk. Product approvals are not guaranteed, while manufacturing and distribution requirements add Capital and execution demands as the business expands.

Currency movements are also relevant because CSL and Telix report in US dollars, while Pro Medicus generates a significant portion of revenue outside Australia.

What Investors May Monitor Through the Rest of 2026

For CSL, underlying earnings performance, restructuring progress and delivery against FY27 net profit growth expectations may provide further information on the business reset.

For Pro Medicus, additional contract wins and conversion of its existing contract Backlog into revenue will remain important operational measures.

For Telix, commercial progress following the Pixclara approval, sales from its existing imaging products and the regulatory pathway for Zircaix remain key developments.

The 2026 updates show three different healthcare strategies. CSL is working through a major operational reset, Pro Medicus continues to expand through long-duration imaging contracts, and Telix is building scale across commercial radiopharmaceutical products while progressing its development pipeline.